Geode Capital Management LLC Has $31.51 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Geode Capital Management LLC increased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 11.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,786,671 shares of the company’s stock after buying an additional 378,136 shares during the quarter. Geode Capital Management LLC’s holdings in Amneal Pharmaceuticals were worth $31,511,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Amneal Pharmaceuticals by 20.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock valued at $4,771,000 after buying an additional 128,772 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Amneal Pharmaceuticals by 13.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after buying an additional 4,115 shares during the last quarter. Rothschild Investment LLC acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter worth approximately $26,000. nVerses Capital LLC bought a new position in shares of Amneal Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, Ritholtz Wealth Management boosted its holdings in shares of Amneal Pharmaceuticals by 19.3% in the 2nd quarter. Ritholtz Wealth Management now owns 159,710 shares of the company’s stock worth $1,014,000 after acquiring an additional 25,869 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 17.46% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of recent analyst reports. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Truist Financial upped their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Stock Up 0.8 %

Shares of AMRX opened at $7.85 on Thursday. The stock’s fifty day simple moving average is $8.38 and its 200-day simple moving average is $7.96. The firm has a market capitalization of $2.43 billion, a PE ratio of -11.54 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.